Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCS-2 in LUTS/BPH
NCT01002664Phase 3Completed
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Start
- May 2010
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing MCS-2 with Placebo (2 arms). Primary endpoint: Total International Prostate Symptom Score at 12 weeks. Started May 2010; status: completed.
02
Drugs
MCS-2
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01002664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01002664.